IGF2BP3 and meningioma: Hao et al. found that the 5-year recurrence-free rate and overall survival rate of IGF2BP3-positive patients were much lower than those of IGF2BP3-negative patients, confirming that IGF2BP3 is a potential independent prognostic biomarker of the high-risk recurrence of meningioma [48].